Roche’s Evrysdi (risdiplam) Receives Health Canada’s Approval for Spinal Muscular Atrophy in Adults and Children

April 16, 2021 Auto Bot Adults, approval, Children, Health Canada, receives, regulatory, Roche, spinal muscular atrophy, Treatment 0

Shots:

  • The approval is based on two studies i.e. FIREFISH & SUNFISH. The FIREFISH study involves assessing Evrysdi in infants aged 2-7mos. with symptomatic Type 1 SMA, and the SUNFISH study assesses Evrysdi in children & young adults aged 2-25yrs. with Type 2 or 3 SMA
  • Evrysdi demonstrated improvement in motor function, 29.3% of participants were able to sit without support for at least 5sec., 85.4% of participants shows event-free survival without permanent ventilation after 12 mos. of treatment
  • Evrysdi is a pre-mRNA splicing modifier of SMN2 designed to treat SMA in patients aged ≥2mos. and is the first at-home administered treatment for SMA

Click here to­ read full press release/ article | Ref: Newswire Canada | Image: Switzerland Global Enterprise

The post Roche’s Evrysdi (risdiplam) Receives Health Canada’s Approval for Spinal Muscular Atrophy in Adults and Children first appeared on PharmaShots.